ARS Pharmaceuticals (SPRY) Interest & Investment Income (2021 - 2026)
ARS Pharmaceuticals (SPRY) posted Interest & Investment Income of -$221000.0 for Q1 2026, down 267.42% sequentially from $132000.0 in Q4 2025, and down 49.32% YoY from -$436106.7 in Q1 2025.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) Interest & Investment Income (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Interest & Investment Income for 6 years, with the latest figure at -$221000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 49.32% year-over-year to -$221000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$168000.0 (down 185.71% YoY) and the FY2025 annual result came in at -$95000.0, down 155.56% from the prior year.
- Interest & Investment Income eased to -$221000.0 in Q1 2026 per SPRY's latest filing, from $132000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $484000.0 in Q3 2024 and troughed at -$339000.0 in Q1 2023.
- A 5-year average of -$6857.1 and a median of -$69500.0 in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income soared 2447.37% in 2024, then slumped 461.9% in 2025.
- Over 5 years, Interest & Investment Income stood at $407000.0 in 2022, then tumbled by 48.4% to $210000.0 in 2023, then tumbled by 156.67% to -$119000.0 in 2024, then soared by 210.92% to $132000.0 in 2025, then sank by 267.42% to -$221000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$221000.0, $132000.0, and $39000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn | -44,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44,000.00 |
| Mar 31, 2026 | -221,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | -118,000.00 |
| Mar 31, 2025 | -148,000.00 |
| Dec 31, 2024 | -119,000.00 |
| Sep 30, 2024 | 484,000.00 |
| Jun 30, 2024 | -21,000.00 |
| Mar 31, 2024 | -173,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | -248,000.00 |
| Mar 31, 2023 | -339,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | -34,000.00 |